Nabriva Therapeutics PLC (NBRVF)

[realfast95]

Gabelli analyst Kevin Kedra downgraded Nabriva Therapeutics AG (NASDAQ: NBRV) from Hold to Sell with a price target of $2.00.

The analyst comments "Our decision to lower our recommendation to Sell is a reflection of NBRV’s current valuation relative to near-term risks. We note that the company’s market capitalization is ahead of several peers with one or more approved antibiotics. We continue to believe that the antibiotic sector is broadly undervalued when taking a long-term view, but we cannot ignore the current market dynamics and near-term risk factors. The risk/reward balance for Nabriva heading into the April 30 PDUFA for Contepo tilts heavily toward the negative as shares trade at a significant premium to our 2020 riskadjusted PMV of $2.00 per share."


https://www.streetinsider.com/Analyst+Comments/Gabelli+Downgrades+Nabriva+Therapeutics+AG+%28NBRV%29+to+Sell/15300910.html